Tin tức & Cập nhật

Chỉ hiển thị Multimedia

Liver transplant tied to better survival than systemic therapy only in nonmetastatic HCC

07 Dec 2025

In patients with nonmetastatic hepatocellular carcinoma (HCC), treatment with upfront liver transplant or liver transplant with bridge systemic therapy results in significantly better improvements in overall survival (OS) compared with systemic therapy only, according to a study.

Liver transplant tied to better survival than systemic therapy only in nonmetastatic HCC

07 Dec 2025

Relapse higher in HBeAg- patients after cessation of TAF vs TDF, entecavir

04 Dec 2025

Patients who discontinue tenofovir alafenamide (TAF) therapy appear to have a higher hepatitis B virus relapse rate than those who ceased entecavir or tenofovir disoproxil fumarate (TDF) therapy, according to a recent study.

Relapse higher in HBeAg- patients after cessation of TAF vs TDF, entecavir

04 Dec 2025

CCBs not associated with variceal haemorrhage in cirrhosis

29 Nov 2025

Patients with cirrhosis using calcium channel blockers (CCBs) are not at increased risk of variceal haemorrhage, as reported in a retrospective study.

CCBs not associated with variceal haemorrhage in cirrhosis

29 Nov 2025

NAFLD/MAFLD carries increased risk of nephrolithiasis

22 Nov 2025

Patients with nonalcoholic fatty liver disease (NAFLD)/metabolic dysfunction–associated fatty liver disease (MAFLD) have an elevated risk of nephrolithiasis, according to a study.

NAFLD/MAFLD carries increased risk of nephrolithiasis

22 Nov 2025

Chronic HCV infection increases susceptibility to pancreatic cancer

19 Nov 2025

Chronic hepatitis C virus (HCV) infection contributes to an increased risk of pancreatic ductal adenocarcinoma (PDAC), as reported in a retrospective study.

Chronic HCV infection increases susceptibility to pancreatic cancer

19 Nov 2025

PFS a potential surrogate marker for OS in advanced BTC trials

13 Nov 2025

In advanced biliary tract cancer (BTC), progression-free survival (PFS) is moderately associated with overall survival (OS) both the trial- and patient-level analyses, while objective response rate (ORR) and disease control rate (DCR) show a low correlation.

PFS a potential surrogate marker for OS in advanced BTC trials

13 Nov 2025

Durvalumab plus chemo delivers sustained survival benefits in advanced BTC

13 Nov 2025 bởi

A 3-year update from the phase III TOPAZ-1 study has shown sustained survival benefit and manageable safety with durvalumab plus gemcitabine and cisplatin (GemCis) relative to placebo among patients with advanced biliary tract cancer (BTC).

Durvalumab plus chemo delivers sustained survival benefits in advanced BTC

13 Nov 2025

Rivaroxaban may prevent PHT-related complications in cirrhosis

13 Nov 2025

Treatment with rivaroxaban appears to improve portal hypertension (PHT)-related complications without increasing the risk of major bleeding in patients with cirrhosis and moderate liver dysfunction, a study has shown.

Rivaroxaban may prevent PHT-related complications in cirrhosis

13 Nov 2025

SAFE score-based approach more effective than current guidelines for liver fibrosis

02 Nov 2025

A recent study has found the proposed population risk stratification approach using the Steatosis-Associated Fibrosis Estimator (SAFE) score to be simpler and more effective than current guidelines.

SAFE score-based approach more effective than current guidelines for liver fibrosis

02 Nov 2025

AIH linked to higher lymphoma, myeloma risks, but not to extrahepatic malignancy

01 Nov 2025

Patients with autoimmune hepatitis (AIH) do not show an increased risk of overall extrahepatic malignancy compared with controls, but they appear to be at greater risk of lymphoma or myeloma, independent of immunosuppressant use, suggests a study.

AIH linked to higher lymphoma, myeloma risks, but not to extrahepatic malignancy

01 Nov 2025

Tin tức & Cập nhật

Lọc theo Chuyên ngành:

Chuyên ngành:

Liver transplant tied to better survival than systemic therapy only in nonmetastatic HCC

Liver transplant tied to better survival than systemic therapy only in nonmetastatic HCC

Relapse higher in HBeAg- patients after cessation of TAF vs TDF, entecavir

Relapse higher in HBeAg- patients after cessation of TAF vs TDF, entecavir

CCBs not associated with variceal haemorrhage in cirrhosis

CCBs not associated with variceal haemorrhage in cirrhosis

NAFLD/MAFLD carries increased risk of nephrolithiasis

NAFLD/MAFLD carries increased risk of nephrolithiasis

Chronic HCV infection increases susceptibility to pancreatic cancer

Chronic HCV infection increases susceptibility to pancreatic cancer

PFS a potential surrogate marker for OS in advanced BTC trials

PFS a potential surrogate marker for OS in advanced BTC trials

Durvalumab plus chemo delivers sustained survival benefits in advanced BTC

Durvalumab plus chemo delivers sustained survival benefits in advanced BTC

Rivaroxaban may prevent PHT-related complications in cirrhosis

Rivaroxaban may prevent PHT-related complications in cirrhosis

SAFE score-based approach more effective than current guidelines for liver fibrosis

SAFE score-based approach more effective than current guidelines for liver fibrosis

AIH linked to higher lymphoma, myeloma risks, but not to extrahepatic malignancy

AIH linked to higher lymphoma, myeloma risks, but not to extrahepatic malignancy